Silverback Therapeutics, Inc. (SBTX) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Silverback Therapeutics, Inc. (SBTX) Healthcare & Pipeline Overview

Silverback Therapeutics, Inc. is a biopharmaceutical company specializing in tissue-targeted therapeutics for chronic viral infections and cancer. Their lead candidate, SBT8230, aims to treat chronic hepatitis B by leveraging TLR8 activation in the liver, positioning them in the competitive biotechnology landscape with a focus on innovative immune-oncology approaches.

What Is the Investment Thesis for SBTX?

Silverback Therapeutics presents a focused investment opportunity within the biotechnology sector, driven by its innovative tissue-targeted approach to treating chronic viral infections and cancer. The company's lead product candidate, SBT8230, targeting chronic hepatitis B virus (HBV) infection, is a key value driver. Successful clinical trials and regulatory approval for SBT8230 could significantly increase the company's market capitalization. With a gross margin of 75.8%, Silverback demonstrates potential for profitability upon commercialization of its products. However, the company's negative profit margin of -203.3% highlights the current reliance on research and development spending. Upcoming clinical trial results for SBT8230 represent a significant catalyst. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Investors should closely monitor the progress of SBT8230 and the company's ability to secure additional funding to support its research and development activities.

Based on FMP financials and quantitative analysis

SBTX Key Highlights

Market Cap of $550M reflects investor valuation of Silverback's pipeline and technology.

• Gross Margin of 75.8% indicates strong potential profitability upon successful commercialization of products.
• Negative P/E ratio of -5.12 due to the company's current lack of profitability as it invests heavily in research and development.
• Profit Margin of -203.3% highlights the significant expenses associated with clinical-stage biopharmaceutical development.
• Focus on tissue-targeted therapeutics differentiates Silverback from competitors and offers potential for improved efficacy and safety.

Who Are SBTX's Competitors?

SBTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SBTX's Key Strengths?

Innovative tissue-targeting technology platform.

• Strong focus on chronic viral infections and cancer.
• Experienced management team.
• Potential for improved efficacy and safety compared to traditional therapies.

What Are SBTX's Weaknesses?

Limited number of products in clinical development.

• High reliance on successful clinical trial outcomes.
• Negative profit margin due to heavy R&D spending.
• Small size compared to established pharmaceutical companies.

What Could Drive SBTX Stock Higher?

Clinical trial results for SBT8230 in chronic HBV patients.

• Potential FDA Fast Track designation for SBT8230.
• Expansion of the company's pipeline of tissue-targeted therapeutics.
• Strategic partnerships and collaborations with larger pharmaceutical companies.

What Are the Key Risks for SBTX?

Financial-distress signal — its Altman Z-Score of -1.83 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for SBT8230 or other pipeline candidates.
• Regulatory hurdles and delays in obtaining marketing approvals.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on securing additional funding to support research and development activities.

What Are the Growth Opportunities for SBTX?

• Expansion of SBT8230 into Additional HBV Patient Subsets: Silverback has the opportunity to expand the use of SBT8230 to treat additional patient populations with chronic HBV infection. This includes exploring its efficacy in patients with different viral genotypes or disease stages. The global market for HBV therapeutics is projected to reach $4.5 billion by 2028, providing a substantial market opportunity for SBT8230 if it demonstrates clinical efficacy across various patient subsets. This expansion could occur within the next 3-5 years following successful clinical trials and regulatory approvals.
• Development of New Tissue-Targeted Therapeutics: Silverback can leverage its expertise in tissue-targeted drug delivery to develop new therapies for other chronic viral infections and cancers. This involves identifying new targets and developing novel therapeutics that can selectively deliver drugs to diseased tissues. The market for targeted therapies is rapidly growing, with a projected market size of $150 billion by 2027. Silverback's pipeline expansion could lead to new revenue streams and increased market share over the next 5-7 years.
• Strategic Partnerships and Collaborations: Silverback can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its therapeutics. This includes partnering with companies that have established sales and marketing infrastructure or expertise in specific therapeutic areas. Strategic alliances can provide Silverback with access to additional funding, resources, and expertise, enhancing its ability to bring new therapies to market more quickly. These partnerships could materialize within the next 2-3 years.
• Advancement of Pipeline Candidates Through Clinical Trials: Silverback's growth is heavily dependent on the successful advancement of its pipeline candidates through clinical trials. This involves conducting rigorous clinical studies to demonstrate the safety and efficacy of its therapeutics. Positive clinical trial results are essential for regulatory approval and commercial success. The company's ability to efficiently manage and execute clinical trials will be a key determinant of its future growth prospects. Clinical trial milestones are expected over the next 1-3 years.
• Expansion into New Geographic Markets: Silverback can expand its geographic reach by commercializing its therapeutics in new markets outside of the United States. This includes targeting markets in Europe, Asia, and other regions where there is a significant unmet need for chronic viral infection and cancer therapies. International expansion can significantly increase the company's revenue potential and market share. This expansion could begin within 3-5 years following regulatory approvals in key international markets.

What Are SBTX's Competitive Advantages?

• Proprietary tissue-targeting technology platform.
• Patent protection for novel therapeutic candidates.
• Expertise in immune-oncology and drug development.
• First-mover advantage in targeting TLR8 for HBV treatment.

What Does SBTX Do?

Silverback Therapeutics, Inc. is a biopharmaceutical company founded in 2016 and headquartered in Seattle, Washington. The company is dedicated to developing innovative, tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Silverback's core technology focuses on leveraging the body's immune system to fight diseases more effectively and with fewer side effects. Their primary product candidate, SBT8230, is being developed as a treatment for chronic hepatitis B virus (HBV) infection. SBT8230 works by targeting TLR8 activation specifically to the liver, aiming to elicit a potent anti-viral immune response. The company's approach involves creating therapies that can precisely target diseased tissues, thereby minimizing the impact on healthy tissues. This targeted approach is designed to improve the efficacy and safety of treatments, offering potential benefits over traditional systemic therapies. Silverback's focus on chronic viral infections and cancer reflects the significant unmet medical needs in these areas and the potential for innovative therapies to make a substantial impact on patient outcomes. The company operates within the highly competitive biotechnology industry, where innovation and clinical success are critical for long-term growth and value creation. Silverback's strategy involves advancing its pipeline of tissue-targeted therapeutics through clinical development, with the goal of bringing new and effective treatments to patients in need.

What Products and Services Does SBTX Offer?

• Develop tissue-targeted therapeutics for chronic viral infections.
• Create therapies for the treatment of cancer.
• Focus on eliciting anti-viral immune responses.
• Target TLR8 activation in specific tissues like the liver.
• Design therapies to minimize impact on healthy tissues.
• Advance a pipeline of therapeutics through clinical development.
• Innovate in the field of immune-oncology.

How Does SBTX Make Money?

• Develop and patent novel tissue-targeted therapeutics.
• Conduct preclinical and clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Potentially commercialize products directly or through partnerships.

What Industry Does SBTX Operate In?

Silverback Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for chronic viral infection and cancer therapies is substantial and growing, driven by increasing prevalence of these diseases and advancements in treatment options. The competitive landscape includes both established pharmaceutical companies and emerging biotechnology firms, all vying for market share. Silverback's tissue-targeted approach aims to differentiate itself by offering more effective and safer therapies compared to traditional systemic treatments. Success in this industry requires strong scientific expertise, successful clinical trials, and the ability to navigate complex regulatory pathways.

Who Are SBTX's Key Customers?

• Patients suffering from chronic hepatitis B virus (HBV) infection.
• Patients with various forms of cancer.
• Healthcare providers who prescribe and administer the company's therapies.
• Hospitals and clinics that utilize the company's products.

Silverback Therapeutics, Inc. Financial Trajectory

Silverback Therapeutics, Inc. (SBTX) reported $33.7M in revenue for Q2 2026, reflecting 48.4% growth compared to the prior quarter. The company recorded a net loss of $62.3M, with diluted EPS of $-0.63. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, SBTX averaged $-0.54 in diluted EPS.

Company Profile

Silverback Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Peter A. Thompson. SBTX has traded publicly since 2020.

How Silverback Therapeutics, Inc. Is Valued

Silverback Therapeutics, Inc. carries a market capitalization of $550M, placing it in the small-cap category. Relative to its peer group, SBTX's quantitative score of 47/100 is roughly in line with the peer average of 50/100.

Key Financial Metrics

Return on assets is -86.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -31.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -34.0%, the inverse of the P/E and a quick read on earnings relative to price.

Silverback Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.83 places it in the distress zone, a signal of elevated financial risk.

Silverback Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 8.3% below estimates on average.

SBTX Financials

SBTX Latest News

No recent news available for SBTX.

SBTX Analyst Consensus

SBTX MoonshotScore

Silverback Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources